Financial Year Ending 30 June 2024
"Throughout the financial year, our team has maintained a sharp focus on executing CLINUVEL's expansion strategy. Despite the increased operational complexity, we have remained aligned with long‑term objectives and successfully achieved our annual targets. Key financial metrics — including revenue, profit, investment, and asset growth — continue to show consistent year-on-year increases whilst expanding the ability to provide SCENESSE® treatment to an increasing number of patients."
Peter Vaughan, Chief Financial Officer